This article is more than 5 years old. Information may no longer be current.
Histogenics enters supply agreement with Collagen Solutions
Click Here to Manage Email Alerts
Histogenics Corporation has announced a supply agreement between the company and Collagen Solutions Ltd. of the United Kingdom.
Under the terms of the agreement, Collagen Solutions will provide Histogenics with additional collagen material sources to use with NeoCart, Histogenics’ regenerative medicine currently in phase 3 clinical trials. NeoCart uses autologous cell therapy, biomaterials and engineering to create tissue implants for repair of knee cartilage.
According to a company press release, the agreement also can be expanded to use in additional Histogenics products sold in non-U.S. markets.
“We are pleased to enter into this partnership with Collagen Solutions in the United Kingdom as they have the historical know-how, leading technical capabilities and unique technology platforms that will provide additional supply capabilities in the United States and potentially serve our future product development requirements for new indications and for our markets outside of the United States,” Adam Gridley, chief executive officer of Histogenics, stated in the release.
Reference: www.histogenics.com